Regional fat distribution by dual-energy X-ray absorptiometry: comparison with anthropometry and application in a clinical trial of growth hormone and exercise.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

The purpose of this study was to determine the suitability of ratios derived from dual-energy X-ray absorptiometry (DXA) whole body scans to assess regional fat distribution in older men and women by comparing them with the waist-to-hip ratio (WHR) and to evaluate their clinical utility by applying them in a clinical trial involving resistance exercise and recombinant human growth hormone. 2.

Why It Was Studied

Sixty-four healthy older adults (39 women and 25 men), aged 65-82 years, served as subjects.

The ratios of trunk fat-to-total fat, trunk fat-to-body weight, trunk fat-to-limb fat and trunk fat % were determined by DXA.

Who Took Part

The abstract describes 39 women taking part.

PubMed indexes the participants as older adults and people over 80, both men and women.

WHR was assessed on the same day, as was the ratio of subscapular/triceps skinfolds in men.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

The women were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

What Was Measured

Cardiovascular disease risk factors, functional capacity and serum lipids were also assessed. 3.

Topics PubMed links to this paper include Absorptiometry, Photon, Adipose Tissue, Anthropometry, Body Constitution, Cardiovascular Diseases, Exercise Therapy and Growth Hormone.

What This Means in Plain Language

The paper is a randomized and double-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 39 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1994 (Clinical science (London, England : 1979)), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.